We recently compiled a list of the Last Week’s Top 10 Stocks Post Double-Digit Gains. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against ...

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of ...

The average one-year price target for Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) has been revised to 16.03 / share. This is an increase of 8.91% from the prior estimate of 14.72 dated July 5, 2023.

Bayer and digital biology company Recursion Inc. entered into a strategic collaboration agreement to leverage Recursion’s purpose-built, artificial intelligence-guided drug discovery platform and ...

Recursion Pharmaceuticals' stock experienced a 10.06% surge on Monday, indicating strong investor confidence in the company's innovations. The completion of BioHive-2 marks a pivotal moment for ...

We recently published a list of Pulse of The Market: Tuesday’s 10 Worst Performers. In this article, we are going to take a look at where Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stands against ...

Fintel reports that on May 9, 2023, Keybanc maintained coverage of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) with a Overweight recommendation. As of April 24, 2023, the average one-year price ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands ...

Recursion on Tuesday announces top-line results of the SYCAMORE trial, studying REC-994 in symptomatic CCM patients. REC-994 met its primary endpoint of safety and tolerability, but there were not yet ...

Hi, everybody. My name is Chris Gibson, Co-Founder and CEO of Recursion, delighted to be joining you on our L(earnings) today. And I'm joined by our Chief R&D and Commercial Officer, Najat Khan and ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best fundamentally strong penny stocks to buy according to analysts. On December 19, TheFly reported that Cathie Wood’s ARK Investment has ...